HRP20020883A2 - STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE AND SALTS THEREOF - Google Patents

STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE AND SALTS THEREOF Download PDF

Info

Publication number
HRP20020883A2
HRP20020883A2 HR20020883A HRP20020883A HRP20020883A2 HR P20020883 A2 HRP20020883 A2 HR P20020883A2 HR 20020883 A HR20020883 A HR 20020883A HR P20020883 A HRP20020883 A HR P20020883A HR P20020883 A2 HRP20020883 A2 HR P20020883A2
Authority
HR
Croatia
Prior art keywords
benzo
methoxyphenyl
phenoxy
ethoxy
hydroxy
Prior art date
Application number
HR20020883A
Other languages
English (en)
Croatian (hr)
Inventor
Najjar Bashore Fadia
Kerry
Dean Minnett Michael
Clark Rickard Eugene
Ann Tingle Cheryl
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20020883A2 publication Critical patent/HRP20020883A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20020883A 2000-05-08 2001-04-30 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE AND SALTS THEREOF HRP20020883A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20323500P 2000-05-08 2000-05-08
PCT/US2001/011736 WO2001085147A2 (fr) 2000-05-08 2001-04-30 Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes

Publications (1)

Publication Number Publication Date
HRP20020883A2 true HRP20020883A2 (en) 2005-02-28

Family

ID=22753086

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020883A HRP20020883A2 (en) 2000-05-08 2001-04-30 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE AND SALTS THEREOF

Country Status (30)

Country Link
EP (1) EP1357903B1 (fr)
JP (1) JP2003535827A (fr)
KR (1) KR100806992B1 (fr)
CN (1) CN1283250C (fr)
AR (1) AR028401A1 (fr)
AT (1) ATE348605T1 (fr)
AU (2) AU5531001A (fr)
BR (1) BR0110620A (fr)
CA (2) CA2691739A1 (fr)
CZ (1) CZ20023651A3 (fr)
DE (1) DE60125416T2 (fr)
DZ (1) DZ3376A1 (fr)
EA (1) EA004871B1 (fr)
EC (1) ECSP014066A (fr)
EG (1) EG24223A (fr)
ES (1) ES2276784T3 (fr)
HR (1) HRP20020883A2 (fr)
HU (1) HUP0302190A3 (fr)
IL (2) IL152699A0 (fr)
MX (1) MXPA02010923A (fr)
NO (1) NO20025219L (fr)
NZ (1) NZ521393A (fr)
PE (1) PE20011255A1 (fr)
PL (1) PL365472A1 (fr)
SK (1) SK286346B6 (fr)
SV (1) SV2002000435A (fr)
TW (1) TWI225787B (fr)
UA (1) UA77941C2 (fr)
WO (1) WO2001085147A2 (fr)
ZA (1) ZA200207651B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
JP4593469B2 (ja) * 2003-09-22 2010-12-08 杏林製薬株式会社 変色改善された５−アミノサリチル酸固形製剤およびその保存方法
WO2016024369A1 (fr) * 2014-08-13 2016-02-18 テバ製薬株式会社 Composition médicinale pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
EP1204656A2 (fr) * 1999-07-29 2002-05-15 Eli Lilly And Company NOUVELLE FORME CRISTALLINE DE CHLORHYDRATE DE 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO b]THIOPHENE
CY2344B1 (en) * 1999-07-29 2004-06-04 Lilly Co Eli A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.

Also Published As

Publication number Publication date
CN1283250C (zh) 2006-11-08
KR20030009477A (ko) 2003-01-29
DE60125416T2 (de) 2007-09-27
EG24223A (en) 2008-11-10
AR028401A1 (es) 2003-05-07
ZA200207651B (en) 2003-12-23
JP2003535827A (ja) 2003-12-02
PL365472A1 (en) 2005-01-10
EP1357903B1 (fr) 2006-12-20
AU2001255310C1 (en) 2006-03-09
EA004871B1 (ru) 2004-08-26
BR0110620A (pt) 2003-04-01
EP1357903A2 (fr) 2003-11-05
CN1545413A (zh) 2004-11-10
NO20025219D0 (no) 2002-10-31
MXPA02010923A (es) 2003-03-27
IL152699A (en) 2009-09-01
ECSP014066A (es) 2002-02-25
NZ521393A (en) 2004-08-27
UA77941C2 (en) 2007-02-15
CA2408563A1 (fr) 2001-11-15
HK1061349A1 (en) 2004-09-17
AU2001255310B2 (en) 2005-03-03
HUP0302190A2 (hu) 2003-10-28
IL152699A0 (en) 2003-06-24
DZ3376A1 (fr) 2001-11-15
PE20011255A1 (es) 2001-12-11
SK15652002A3 (sk) 2003-04-01
AU5531001A (en) 2001-11-20
DE60125416D1 (de) 2007-02-01
AU2001255310B8 (en) 2005-03-10
SK286346B6 (en) 2008-07-07
EA200201186A1 (ru) 2003-08-28
WO2001085147A2 (fr) 2001-11-15
TWI225787B (en) 2005-01-01
ES2276784T3 (es) 2007-07-01
WO2001085147A3 (fr) 2003-08-28
NO20025219L (no) 2002-10-31
ATE348605T1 (de) 2007-01-15
SV2002000435A (es) 2002-10-24
HUP0302190A3 (en) 2009-03-30
CZ20023651A3 (cs) 2003-02-12
KR100806992B1 (ko) 2008-02-25
CA2691739A1 (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
EA028769B1 (ru) Фармацевтические композиции, содержащие рифаксимин и аминокислоты, способ их получения и их применение
CZ253794A3 (en) Pharmaceutical preparation for inhibiting endometriosis
CZ20023775A3 (cs) Zolpidem hemitartrát
CA3235361A1 (fr) Polymorphes du sel chlorhydrate de linaprazan glurate
CZ305398A3 (cs) Benzothiaziny, prostředky s jejich obsahem, a způsoby, při kterých se těchto sloučenin využívá
AU2001255310B8 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo(b)thiophene and salts thereof
TWI607006B (zh) 細胞凋亡蛋白抑制劑之固體口服調配物及晶型
US7122203B2 (en) Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
AU2001255310A1 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo(b)thiophene and salts thereof
WO2017174046A1 (fr) Formulation de citrate d'ixazomib de forme 3
WO2024149834A1 (fr) Polymorphes de sel de bromhydrate de linaprazan glurate
AU2005200809B2 (en) Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof
EP1757291A2 (fr) Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
HK1061349B (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
CN120035591A (zh) 用于治疗或预防高尿酸血症或痛风的化合物的固体晶型
TW202521117A (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
EA043571B1 (ru) Соли сулькардина
HK40020497A (en) Crystalline solid forms of salts, processes for making, and methods of use

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBC Application rejected